natgillin/translations-raw huggingface dataset:
Effect of teriflunomide on oral contraceptives: 0.03 mg ethinylestradiol and 0.15 mg levonorgestrel There was an increase in mean ethinylestradiol Cmax and AUC0-24 (1.58- and 1.54-fold, respectively) and levonorgestrel Cmax and AUC0-24 (1.33- and 1.41-fold, respectively) following repeated doses of teriflunomide. 
Učinak teriflunomida na oralne kontraceptive: 0,03 mg etinilestradiola i 0,15 mg levonorgestrela Nakon ponovljenih doza teriflunomida povećali su se srednji Cmax i AUC0-24 etinilestradiola (1,58 puta odnosno 1,54 puta), dok se Cmax levonorgestrela povećao 1,33 puta, a AUC 0-24 1,41 puta.
It is recommended that patients receiving teriflunomide are not treated with cholestyramine or activated charcoal because this leads to a rapid and significant decrease in plasma concentration unless an accelerated elimination is desired. 
Osim ako je ubrzana eliminacija poželjna, ne preporučuje se bolesnike koji primaju teriflunomid liječiti kolestiraminom ili aktivnim ugljenom jer oni uzrokuju brzo i značajno smanjenja koncentracije lijeka u plazmi.
However, a 25% decrease in peak international normalised ratio (INR) was observed when teriflunomide was coadministered with warfarin as compared with warfarin alone. 
Međutim, kada se teriflunomid primjenjivao istodobno s varfarinom, primijećeno je smanjenje vršnog internacionalnog normaliziranog omjera (INR) od 25% u odnosu na varfarin primijenjen samostalno.
During treatment During treatment with teriflunomide the following should be monitored: 
Tijekom liječenja teriflunomidom treba kontrolirati:
Change relative to placebo (CI95%) Number of unique active lesions /scan Change relative to placebo (CI95%)  p<0.0001  p<0.001  p<0.01  p<0.05 compared to placebo (1) BOD: burden of disease: total lesion volume (T2 and T1 hypointense) in ml 
∗∗∗∗ p<0,0001 ∗∗∗ p<0,001 ∗∗ p<0,01 ∗ p<0,05 u usporedbi s placebom (1) BOD (engl. burden of disease): opterećenje bolešću: ukupan volumen lezija (hipointenzivne lezije na T2 i T1) u ml
Alternatively, when cholestyramine is not available, activated charcoal 50 g twice a day for 11 days may also be used. 
Ako kolestiramin nije dostupan, alternativno se može primijeniti aktivni ugljen u dozi od 50 g dvaput na dan tijekom 11 dana.
If this is not well tolerated, cholestyramine 4 g three times a day for 11 days can be used. 
Ako se ta doza ne podnosi dobro, može se primijeniti kolestiramin u dozi od 4 g triput na dan tijekom 11 dana.
Treatment was discontinued in 5 patients with peripheral neuropathy on teriflunomide 14 mg. Recovery following treatment discontinuation was reported in 4 of these patients. 
Liječenje je prekinuto u 5 bolesnika s perifernom neuropatijom koji su uzimali teriflunomid u dozi od 14 mg.
The frequency of elevations above 3-fold ULN and higher was balanced across treatment groups. 
Učestalost povišenja iznad trostrukog GGN-a i više bila je podjednaka u svim liječenim skupinama.
• For women of child-bearing potential o to emphasise the need for effective contraception during treatment with teriflunomide o to stop treatment with teriflunomide immediately if they suspect they might be pregnant and also to contact their doctor immediately 
• informacije za žene reproduktivne dobi o mora se naglasiti potreba za primjenom djelotvorne kontracepcije tijekom liječenja teriflunomidom o ako posumnja na trudnoću, bolesnica mora odmah prekinuti liječenje teriflunomidom i mora se odmah obratiti liječniku
• Complete blood cell count including differential white blood cell and platelet count. 
• kompletnu krvnu sliku, uključujući diferencijalnu sliku leukocita i broj trombocita.
The median EDSS score at baseline was 2.50; 298 patients (25.5%) had an EDSS score › 3.5 at baseline. 
Medijan EDSS rezultata na početku liječenja iznosio je 2,50: 298 bolesnika (25,5%) je na početku liječenja imalo EDSS rezultat > 3,5.
AUBAGIO should not be used in children and adolescents under 18 years of age. 
AUBAGIO se ne smije primjenjivati u djece i adolescenata mlađih od 18 godina jer učinci lijeka u toj dobnoj skupini nisu poznati.
The primary biotransformation pathway for teriflunomide is hydrolysis, with oxidation being a minor pathway. 
Primarni biotransformacijski put teriflunomida je hidroliza, a oksidacija je sporedni put.
- severe skin reactions which might include symptoms of skin rash, blistering, or ulcers in your mouth - severe infections or sepsis (a potentially life-threatening type of infection) which might include symptoms of high fever, shaking, chills, reduced urine flow, or confusion - serious liver disease which might include symptoms of yellowing of your skin or the whites of your eyes, darker urine than normal, unexplained nausea and vomiting, or abdominal pain - inflammation of the lungs which might include symptoms of shortness of breath or persistent cough - inflammation of the pancreas which might include symptoms of severe pain in the upper abdominal area that may also be felt in your back, nausea, or vomiting 
- teške kožne reakcije koje mogu uključivati simptome osipa na koži, mjehurića ili vrijedovi u ustima - teške infekcije ili sepsu (vrsta infekcije potencijalno opasna po život) koje mogu uključivati simptome visoke vrućice, drhtavice, zimice, smanjenog protoka mokraće ili smetenosti - ozbiljnu bolest jetre koja može uključivati simptome žute boje kože ili bjeloočnica, tamniju mokraću nego inače, neobjašnjivu mučninu i povraćanje ili bol u trbuhu - upalu pluća koja može uključivati simptome nedostatka zraka ili kašlja koji ne prolazi
If an accelerated elimination procedure is not used, teriflunomide plasma levels can be expected to be above 0.02 mg/l for an average of 8 months, however, in some patients it may take up to 2 years to reach plasma concentration below 0.02 mg/l. 
Bez postupka ubrzane eliminacije očekuje se da će koncentracija teriflunomida u plazmi biti iznad 0,02 mg/l tijekom prosječno 8 mjeseci, iako u pojedinih bolesnika može biti potrebno i do 2 godine kako bi se koncentracija lijeka u plazmi spustila ispod 0,02 mg/l.
Package leaflet: Information for the patient AUBAGIO 14 mg film-coated tablets teriflunomide 
Uputa o lijeku: Informacije za bolesnika AUBAGIO 14 mg filmom obložene tablete teriflunomid
All patients had a definite diagnosis of MS (based on McDonald criteria (2005)), exhibited a relapsing clinical course, with or without progression, and experienced at least 1 relapse over the year preceding the trial or at least 2 relapses over the 2 years preceding the trial. 
Svi su bolesnici imali definitivno potvrđenu dijagnozu multiple skleroze (prema McDonaldovim kriterijima (2005)), relapsni klinički tijek bolesti, s progresijom ili bez nje te su imali najmanje 1 relaps u godini koja je prethodila ispitivanju ili najmanje 2 relapsa tijekom 2 godine koje su prethodile ispitivanju.
How to take AUBAGIO 
Kako uzimati AUBAGIO
If cholestyramine 8 g three times a day is not well-tolerated, cholestyramine 4 g three times a day can be used. 
Ako se kolestiramin u dozi od 8 g triput na dan ne podnosi dobro, može se primijeniti kolestiramin u dozi od 4 g triput na dan.
Hypersensitivity reactions (immediate or delayed) including anaphylaxis and angioedema 
Poremećaji imunološko g sustava blage alergijske reakcije reakcije preosjetljivo sti (trenutne ili odgođene) uključujući anafilaksiju i angioedem
All patients had a definite diagnosis of MS (based on McDonald criteria (2001)), exhibited a relapsing clinical course, with or without progression, and experienced at least 1 relapse over the year preceding the trial or at least 2 relapses over the 2 years preceding the trial. 
Svi su bolesnici imali definitivno potvrđenu dijagnozu multiple skleroze (prema McDonaldovim kriterijima (2001)), relapsni klinički tijek bolesti, s progresijom ili bez nje te su imali najmanje 1 relaps u godini koja je prethodila ispitivanju ili najmanje 2 relapsa tijekom 2 godine koje su prethodile ispitivanju.
Tablet core lactose monohydrate maize starch microcrystalline cellulose sodium starch glycolate (Type A) hydroxypropylcellulose magnesium stearate 
Jezgra tablete laktoza hidrat kukuruzni škrob celuloza, mikrokristalična natrijev škroboglikolat (vrste A) hidroksipropilceluloza magnezijev stearat
Each tablet contains 14 mg of teriflunomide. 
Jedna tableta sadrži 14 mg teriflunomida.
How AUBAGIO works 
Kako djeluje AUBAGIO
The patient must be advised that if there is any delay in onset of menses or any other reason to suspect pregnancy, they must notify the physician immediately for pregnancy testing, and if positive, the physician and patient must discuss the risk to the pregnancy. 
Bolesnicu se mora upozoriti da se u slučaju bilo kakvog kašnjenja menstruacije ili bilo kojeg drugog razloga zbog kojeg se sumnja na trudnoću mora odmah obratiti liječniku radi testiranja na trudnoću.
The treatment should be initiated and supervised by a physician experienced in the management of multiple sclerosis. 
4.2 Doziranje i način primjene Liječenje mora započeti i nadzirati liječnik s iskustvom u liječenju multiple skleroze.
A mean decrease less than 15% from baseline affecting white blood cell count has been observed (see section 4.8). 
Primijećena je srednja vrijednost smanjenja broja leukocita od manje od 15% u odnosu na početne vrijednosti (vidjeti dio 4.8).
• Risk of hepatic effects o liver function tests are needed prior to treatment and periodically during treatment o To educate the patient about the signs and symptoms of liver disease and the need to report to their HCP if they experience any of them 
• rizik od učinaka na jetru o prije liječenja te periodički tijekom liječenja treba provoditi testove jetrene funkcije o liječnik mora educirati bolesnike o znakovima i simptomima jetrene bolesti te o potrebi da sve znakove i simptome koje primijetite prijave zdravstvenom radniku
A total of 1169 patients with RMS were randomised in TOWER to receive 7 mg (n=408) or 14 mg (n=372) of teriflunomide or placebo (n= 389) for a variable treatment duration ending at 48 weeks after last patient randomised. 
U ispitivanju TOWER ukupno je 1169 bolesnika s RMS-om randomizirano u skupinu koja je primala teriflunomid u dozi od 7 mg (n=408) ili 14 mg (n=372) ili u skupinu koja je primala placebo (n=389) u sklopu liječenja čije je trajanje bilo varijabilno i koje je završavalo 48 tjedana nakon randomizacije posljednjeg bolesnika.
In particular, tell your doctor or pharmacist if you are taking any of the following: - leflunomide, methotrexate and other medicines that affect the immune system (often called immunosuppressants or immunomodulators) - rifampicin (a medicine used to treat tuberculosis and other infections) - carbamazepine, phenobarbital, phenytoin for epilepsy - St John's wort (a herbal medicine for depression) - repaglinide, pioglitazone, nateglinide, or rosiglitazone for diabetes - daunorubicin, doxorubicin, paclitaxel, or topotecan for cancer - duloxetine for depression, urinary incontinenece or in kidney disease in diabetics - alosetron for the management of severe diarrhea - theophylline for asthma - tizanidine, a muscle relaxant - warfarin, an anticoagulant used to make the blood thinner (i.e. more fluid) in order to avoid blood clots - oral contraceptives (containing ethinylestradiol and levonorgestrel) 
Osobito recite liječniku ili ljekarniku ako uzimate neki od sljedećih lijekova: - leflunomid, metotreksat i druge lijekove koji utječu na imunološki sustav (često se nazivaju imunosupresivima ili imunomodulatorima) - rifampicin (lijek koji se koristi za liječenje tuberkuloze i drugih infekcija) - karbamazepin, fenobarbital, fenitoin za epilepsiju - gospinu travu (biljni lijek za depresiju) - repaglinid, pioglitazon, nateglinid ili roziglitazon za šećernu bolest - danorubicin, doksorubicin, paklitaksel ili topotekan za rak
The risk of a second clinical attack over 2 years was 35.9% in the placebo group and 24.0% in the teriflunomide 14 mg treatment group (hazard ratio: 0.57, 95% confidence interval: 0.38 to 0.87, p=0.0087). 
Rizik od drugog kliničkog napadaja tijekom 2 godine bio je 35,9% u placebo skupini i 24,0% u skupini liječenoj teriflunomidom u dozi od 14 mg (omjer hazarda:
Based on individual prediction of pharmacokinetic parameters using the PopPK model of teriflunomide in healthy volunteers and MS patients, median t1/2z was approximately 19 days after repeated doses of 14 mg. After a single intravenous administration, the total body clearance of teriflunomide is 30.5 ml/h. 
Na temelju pojedinačnih previđanja farmakokinetičkih parametara dobivenih modelom populacijske farmakokinetičke analize primjene teriflunomida u zdravih dobrovoljaca i oboljelih od multiple skleroze, medijan t1/2z iznosio je približno 19 dana nakon ponovljenih doza od 14 mg.
A mean decrease affecting white blood cell (WBC) count (<15% from baseline levels, mainly neutrophil and lymphocytes decrease) was observed in placebo-controlled trials with AUBAGIO, although a greater decrease was observed in some patients. 
U placebom kontroliranim ispitivanjima lijeka AUBAGIO primijećeno je smanjenje srednje vrijednosti broja leukocita (<15% u odnosu na početne vrijednosti, uglavnom pad broja neutrofila i limfocita), a u nekih je bolesnika to smanjenje bilo još i veće.
Teriflunomide is contraindicated in this population (see section 4.3). 
Teriflunomid je kontraindiciran u toj populaciji (vidjeti dio 4.3).
AUBAGIO 14 mg tablets teriflunomide 
AUBAGIO 14 mg tablete teriflunomid
Pharmacokinetic interactions of teriflunomide on other substances 
Farmakokinetičke interakcije teriflunomida s drugim tvarima
- you have severe skin reactions. 
- teške kožne reakcije
- if you are allergic to teriflunomide or any of the other ingredients of this medicine (listed in section 6), - if you have severe liver problems, - if you are pregnant, think you may be pregnant, or are breast-feeding, - if you suffer from a serious problem which affects your immune system e.g. acquired immunodeficiency syndrome (AIDS), - if you have a serious problem with your bone marrow, or if you have low numbers of red or white cells in your blood or a reduced number of blood platelets, - if you are suffering from a serious infection, - if you have severe kidney problems which require dialysis, - if you have very low levels of proteins in your blood (hypoproteinaemia), If you are not sure, talk to your doctor or pharmacist before taking this medicine. 
- ako patite od ozbiljne bolesti koja utječe na vaš imunološki sustav (npr. sindroma stečene imunodeficijencije (AIDS-a)), - ako imate ozbiljnih tegoba s koštanom srži ili ako imate nizak broj crvenih ili bijelih krvnih stanica u krvi ili smanjen broj krvnih pločica, - ako bolujete od ozbiljne infekcije, - ako imate teških problema s bubrezima koji zahtijevaju dijalizu, - ako imate vrlo nisku razinu proteina u krvi (hipoproteinemija).
What AUBAGIO is used for 
Za što se AUBAGIO koristi
Before starting treatment with teriflunomide the following should be assessed: 
Prije liječenja Prije početka liječenja teriflunomidom treba provjeriti:
• Potential risk of teratogenicity o To check pregnancy status before starting treatment o To educate female patients of child-bearing potential on the need for effective contraception before starting, and during treatment with teriflunomide o To inform their doctor immediately if they stop contraception, or prior to changing contraceptive measures o If female patients become pregnant despite using contraceptive measures, they should stop teriflunomide and contact their doctor immediately who should: Consider and discuss with the patient the accelerated elimination procedure encourage them to enrol in a pregnancy registry (in countries where a pregnancy registry is on-going), 
• potencijalan rizik od teratogenih učinaka o liječnik mora provjeriti status trudnoće prije početka liječenja o liječnik mora educirati bolesnice reproduktivne dobi o potrebi primjene djelotvorne kontracepcije prije početka liječenja teriflunomidom te za vrijeme njegova trajanja o liječnik mora reći bolesnicima da odmah obavijeste svoga liječnika ako prestanu koristiti kontracepciju ili namjeravaju promijeniti metodu kontracepcije o ako bolesnica zatrudni unatoč primjeni kontracepcije, mora prekinuti liječenje teriflunomidom i odmah se obratiti svome liječniku.
For patients testing positive in tuberculosis screening, treat by standard medical practice prior to therapy with AUBAGIO. 
Prije liječenja lijekom AUBAGIO bolesnike s pozitivnim nalazom testa na tuberkulozu liječite sukladno standardnoj medicinskoj praksi.
Repeated doses of teriflunomide decreased mean Cmax and AUC of caffeine (CYP1A2 substrate) by 18% and 55%, respectively, suggesting that teriflunomide may be a weak inducer of CYP1A2 in vivo. 
Učinak teriflunomida na supstrat izoenzima CYP1A2: kofein Nakon ponovljenih doza teriflunomida srednji Cmax kofeina (supstrata CYP1A2) smanjio se za 18%, a srednji AUC za 55%, što upućuje na to da bi teriflunomid mogao biti slab induktor izoenzima CYP1A2 in vivo.
Most cases were described as diffuse or generalised over the scalp (no complete hair loss reported) and occurred most often during the first 6 months and with resolution in 121 of 139 (87.1%) patients treated with teriflunomide 14 mg. Discontinuation because of alopecia was 1.3% in the teriflunomide 14 mg teriflunomide group, versus 0.1% in the placebo group. 
Većina slučajeva opisana je kao raširena ili generalizirana pojava na tjemenu (nije prijavljen potpun gubitak kose), koja se najčešće javila tijekom prvih 6 mjeseci, a povukla se u 121 od 139 (87,1%) bolesnika liječenih teriflunomidom u dozi od 14 mg.
Severe renal impairment had no impact on the pharmacokinetic of teriflunomide. 
Teško oštećenje bubrežne funkcije nije utjecalo na farmakokinetiku teriflunomida.
Influenza, Upper respiratory tract infection, Urinary tract infection, Bronchitis, Sinusitis, Pharyngitis, Cystitis, Gastroenteritis viral, 
Infekcije i infestacije gripa, infekcija gornjih dišnih putova, infekcija mokraćnih putova, bronhitis, sinusitis, faringitis, cistitis, virusni gastroenteritis, oralni herpes, infekcija zuba, laringitis, atletsko stopalo teške infekcije,
Tell your doctor immediately, if you notice any of the following serious side effects: - allergic reactions which might include symptoms of rash, hives, swelling of lips, tongue or face or sudden difficulty breathing. 
- alergijsku reakciju koja može uključivati simptome osipa, koprivnjače, oticanja usana, jezika ili lica ili naglo otežanog disanja.
The elimination of teriflunomide from the circulation can be accelerated by administration of cholestyramine or activated charcoal, presumably by interrupting the reabsorption processes at the intestinal level. 
Postupak ubrzane eliminacije: kolestiramin i aktivni ugljen Eliminacija teriflunomida iz krvotoka može se ubrzati primjenom kolestiramina ili aktivnog ugljena, koji najvjerojatnije prekidaju postupak ponovne apsorpcije u crijevima.
Route/method of administration 
Put/način primjene lijeka
Effect of teriflunomide on CYP2C8 substrate: repaglinide There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively), following repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of CYP2C8 in vivo. 
Učinak teriflunomida na supstrat izoenzima CYP2C8: repaglinid Nakon ponovljenih doza teriflunomida srednji Cmax repaglinida povećao se 1,7 puta, a srednji AUC 2,4 puta, što upućuje na to da je teriflunomid inhibitor CYP2C8 in vivo.
Your doctor may do blood tests to check your white blood cells if you think you have an infection. 
Ako mislite da imate infekciju, liječnik će možda napraviti krvne pretrage kako bi provjerio broj bijelih krvnih stanica.
The safety of teriflunomide in individuals with latent tuberculosis infection is unknown, as tuberculosis screening was not systematically performed in clinical studies. 
Budući da se u kliničkim ispitivanjima nije provodio sustavni probir na tuberkulozu, sigurnost teriflunomida u osoba s latentnom tuberkulozom nije poznata.
This loss of myelin is called demyelination. 
Taj gubitak mijelina naziva se demijelinizacijom i onemogućuje pravilan rad živaca.
Effect of teriflunomide on organic anion transporter 3 (OAT3) substrates There was an increase in mean cefaclor Cmax and AUC (1.43- and 1.54-fold, respectively), following repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of OAT3 in vivo. 
Učinak teriflunomida na supstrate organskog anionskog transportera 3 (OAT3) Nakon ponovljenih doza teriflunomida srednji Cmax cefaklora povećao se 1,43 puta, a srednji AUC 1,54 puta, što upućuje na to da je teriflunomid inhibitor OAT3 in vivo.
Teriflunomide is contraindicated in patients with severe hepatic impairment (see section 4.3). 
Teriflunomid je kontraindiciran u bolesnika s teškim oštećenjem jetrene funkcije (vidjeti dio 4.3).
ILD may be fatal. 
Intersticijska plućna bolest može biti smrtonosna.
A consistent treatment effect on relapses and time to 3-month sustained disability progression in a subgroup of patients in TEMSO (n 127) with high disease activity was observed. 
U ispitivanju TEMSO je u podskupini bolesnika s bolešću visokoga stupnja aktivnosti primijećen konzistentan učinak liječenja na relapse i vrijeme do tromjesečne trajne progresije onesposobljenosti.
Severe skin reactions Cases of severe skin reactions have been reported with teriflunomide post-marketing (see section 4.4). 
Tijekom primjene teriflunomida nakon stavljanja lijeka u promet prijavljeni su slučajevi teških kožnih reakcija (vidjeti dio 4.4).
- cefaclor, benzylpenicillin (penicillin G), ciprofloxacin for infections - indometacin, ketoprofen for pain or inflammation - furosemide for heart disease - cimetidine for reducing gastric acid - zidovudine for HIV infection - rosuvastatin, simvastatin, atorvastatin, pravastatin for hypercholesterolemia (high cholesterol) - sulfasalazine for inflammatory bowel disease or rheumatoid arthritis - cholestyramine for high cholesterol or relief from itching in liver disease - activated charcoal to reduce absorption of medicines or other substances 
- zidovudin za HIV infekciju - rosuvastatin, simvastatin, atorvastatin, pravastatin za hiperkolesterolemiju (visok kolesterol) - sulfasalazin za upalnu bolest debelog crijeva ili reumatoidni artritis - kolestiramin za visok kolesterol ili ublažavanje svrbeža kod bolesti jetre - aktivni ugljen za smanjenje apsorpcije lijekova ili drugih tvari.
Teriflunomide is contraindicated in pregnancy (see section 4.3). 
Teriflunomid je kontraindiciran tijekom trudnoće (vidjeti dio 4.3).
Vomiting, Toothache 
- proljev, mučnina
A total of 1088 patients with RMS were randomised in TEMSO to receive 7 mg (n=366) or 14 mg (n=359) of teriflunomide or placebo (n= 363) for 108 weeks duration. 
U ispitivanju TEMSO ukupno je 1088 bolesnika s RMS-om randomizirano u skupinu koja je primala teriflunomid u dozi od 7 mg (n=366) ili 14 mg (n=359) ili u skupinu koja je primala placebo (n=363) tijekom 108 tjedana.
Fertility was unaffected in rats despite adverse effects of teriflunomide on male reproductive organs, including reduced sperm count. 
Unatoč štetnim učincima teriflunomida na reproduktivne organe u mužjaka, uključujući i smanjeni broj spermatozoida, teriflunomid nije utjecao na plodnost u štakora.
PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING WALLET 
PODACI KOJI SE MORAJU NALAZITI NA SREDNJEM PAKIRANJU KARTONSKI OVITAK
However, teriflunomide is contraindicated in patients with severe hepatic impairment (see sections 4.2 and 4.3). 
Međutim, teriflunomid je kontraindiciran u bolesnika s teškim oštećenjem jetrene funkcije (vidjeti dijelove 4.2 i
• Complete blood cell counts should be performed based on clinical signs and symptoms (e.g. infections) during treatment. 
• tijekom liječenja treba napraviti kompletnu krvnu sliku na temelju kliničkih znakova i simptoma
Since teriflunomide is highly protein bound and as the binding is dependent upon the concentrations of albumin, unbound plasma teriflunomide concentrations are expected to be increased in patients with hypoproteinaemia, e.g. in nephrotic syndrome. 
očekuje se da će koncentracije nevezanog teriflunomida u plazmi biti povišene u bolesnika s hipoproteinemijom, npr. u nefrotskom sindromu.